Barrier to autointegration factor 1, procollagen‐lysine, 2‐oxoglutarate 5‐dioxygenase 3, and splicing factor 3b subunit 4 as early‐stage cancer decision markers and drivers of hepatocellular carcinoma

Shen, Qingyu; Eun, Jung Woo; Lee, Kyuho; Kim, Hyung Seok; Yang, Hee Doo; Kim, Sang Yean; Lee, Eun Kyung; Kim, Taemook; Kang, Keunsoo; Kim, Seongchan; Min, Dal Hee; Oh, Soon Nam; Lee, Young Joon; Moon, Hyuk; Ro, Simon Weonsang; Park, Won Sang; Lee, Jung Young; Nam, Suk Woo

doi:10.1002/hep.29606

Cited by 93 publications

(101 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pirarubicin (THP) is an important chemotherapy agent of TACE that is usually used in HCC combination therapy. 6,35 Interestingly, we found that THP, as an inhibitor for MARCH1, could accelerate cell apoptosis and decrease the proliferation, migration and invasion in HCC cells also via the PI3K-AKT-β-catenin signalling pathway. This result suggested that the powerful anticancer molecular mechanism of THP was partially mediated by the down-regulated expression of MARCH1 in HCC cells.…”

Section: Discussionmentioning

confidence: 88%

“…Similarly, THP, an anthracycline anticancer drug, is clinically approved for treating various cancers and as a first-line treatment chemotherapeutic for advanced HCC patients. 6,20 Interestingly, we found that THP could suppress MARCH1 expression in proteins. For this, we analysed…”

Section: March1 Is Up-regulated In Hcc Tissues and Cell Linesmentioning

confidence: 88%

“…1 Liver cancer is the second leading cause of cancerrelated deaths globally. 5,6 It is well known that hepatocarcinogenesis is a complex multi-step process, that the altering of many signalling cascades could affect important oncogenes and tumour suppressors, and that molecular-targeted therapies, such as Sorafenib, which is a small molecular protein kinase inhibitor, could be effective in treating advanced cancer. 1,2 HCC usually appears in patients with cirrhosis related to various etiologies.…”

Section: Introductionmentioning

confidence: 99%

“…4 However, most patients with HCC are diagnosed at late stages, when the beneficial treatments of hepatic resection, ablation and liver transplantation cannot be applied; thus, only a minority of patients with early-stage HCC are eligible for this procedure. 5,6 It is well known that hepatocarcinogenesis is a complex multi-step process, that the altering of many signalling cascades could affect important oncogenes and tumour suppressors, and that molecular-targeted therapies, such as Sorafenib, which is a small molecular protein kinase inhibitor, could be effective in treating advanced cancer. 3,7 Therefore, it is urgent to explore more efficient molecular-targeted therapeutic strategies for advanced HCC treatment.…”

mentioning

confidence: 99%

See 3 more Smart Citations

MARCH1 encourages tumour progression of hepatocellular carcinoma via regulation of PI3K‐AKT‐β‐catenin pathways

Xie

Dai

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Membrane‐associated RING‐CH‐1 (MARCH1) is a membrane‐anchored E3 ubiquitin ligase that is involved in a variety of cellular processes. MARCH1 was aberrantly expressed as a tumour promoter in ovarian cancer, but the signalling about the molecular mechanism has not yet been fully illuminated. Here, we first determined that MARCH1 was obviously highly expressed in human hepatocellular carcinoma samples and cells. In addition, our findings demonstrated that the proliferation, migration and invasion of hepatocellular carcinoma were suppressed, but the apoptosis was increased, as a result of MARCH1 knockdown by either siRNA targeting MARCH1 or pirarubicin treatment. Conversely, the proliferation, migration and invasion of hepatocellular carcinoma were obviously accelerated, and the apoptosis was decreased, by transfecting the MARCH1 plasmid to make MARCH1 overexpressed. Moreover, in vivo, the results exhibited a significant inhibition of the growth of hepatocellular carcinoma in nude mice, which were given an intra‐tumour injection of siRNA targeting MARCH1. Furthermore, our study concluded that MARCH1 functions as a tumour promoter, and its role was up‐regulated the PI3K‐AKT‐β‐catenin pathways both in vitro and in vivo. In summary, our work determined that MARCH1 has an important role in the development and progression of hepatocellular carcinoma and may be used as a novel potential molecular therapeutic target in the future treatment of hepatocellular carcinoma.

show abstract

Section: Discussionmentioning

confidence: 88%

Section: March1 Is Up-regulated In Hcc Tissues and Cell Linesmentioning

confidence: 88%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

MARCH1 encourages tumour progression of hepatocellular carcinoma via regulation of PI3K‐AKT‐β‐catenin pathways

Xie

Dai

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…Splicing factor 3B subunit 4 (SF3B4) encodes a core protein in the mammalian SF3b complex, which is part of the U2-type spliceosome that helps tether the U2 snRNP to the branch site. SF3B4 was overexpressed in a large cohort of HCC patients, and this aberrant overexpression was significantly associated with poor prognosis in HCC patients 96 . Aberrant expression of SF3B4 was demonstrated to modulate the expression of cell cycle and EMT proteins through spliceosome effects on the tumor suppressor kruppel-like factor 4 (KLF4) in hepatocellular carcinoma (HCC).…”

Section: The Pathologic Roles Of Rna Variations In Liver Cancermentioning

confidence: 96%

Pathogenic diversity of RNA variants and RNA variation-associated factors in cancer development

Yang

Nam

2020

Exp Mol Med

Self Cite

View full text Add to dashboard Cite

Recently, with the development of RNA sequencing technologies such as next-generation sequencing (NGS) for RNA, numerous variations of alternatively processed RNAs made by alternative splicing, RNA editing, alternative maturation of microRNA (miRNA), RNA methylation, and alternative polyadenylation have been uncovered. Furthermore, abnormally processed RNAs can cause a variety of diseases, including obesity, diabetes, Alzheimer's disease, and cancer. Especially in cancer development, aberrant RNAs caused by deregulated RNA modifiers or regulators are related to progression. Accumulating evidence has reported that aberrant RNAs promote carcinogenesis in many cancers, including liver cancer, leukemia, melanoma, lung cancer, breast cancer, and other cancers, in which abnormal RNA processing occurs in normal cells. Therefore, it is necessary to understand the precise roles and mechanisms of disease-related RNA processing in various cancers for the development of therapeutic interventions. In this review, the underlying mechanisms of variations in the RNA life cycle and the biological impacts of RNA variations on carcinogenesis will be discussed, and therapeutic strategies for the treatment of tumor malignancies will be provided. We also discuss emerging roles of RNA regulators in hepatocellular carcinogenesis.

show abstract

Recent Advances in RNA Therapeutics and RNA Delivery Systems Based on Nanoparticles

Shin

Park

Yim

et al. 2018

Advanced Therapeutics

View full text Add to dashboard Cite

Recently, there have been significant advances in the field of RNA‐based therapeutics harnessing exogenous RNAs including small interfering RNA (siRNA), microRNA (miRNA) mimics, and in vitro transcribed (IVT) mRNAs. RNA‐based therapeutics are one of the most attractive classes of drugs for treating a variety of diseases. In principle, RNA‐based therapeutics offer numerous advantages compared to the conventional small‐molecule‐based therapies. However, there are several drawbacks to overcome in the application of RNA‐based therapeutics, including the instability of RNAs and presence of various biological barriers. In the past decades, there have been various attempts to overcome these key challenges. Here, the authors present an overview of RNA‐based therapeutics and recent advances including their delivery systems and clinical applications. In addition, the current challenges of RNA‐based drugs are discussed, followed by perspectives with regard to the development of these promising drug candidates to elicit successful clinical outcomes.

show abstract

Barrier to autointegration factor 1, procollagen‐lysine, 2‐oxoglutarate 5‐dioxygenase 3, and splicing factor 3b subunit 4 as early‐stage cancer decision markers and drivers of hepatocellular carcinoma

Abstract: The findings suggest molecular markers of BANF1, PLOD3, and SF3B4 indicating early-stage HCC in precancerous lesion, and also suggest drivers for understanding the development of hepatocarcinogenesis. (Hepatology 2018;67:1360-1377).

Cited by 93 publications

References 21 publications

MARCH1 encourages tumour progression of hepatocellular carcinoma via regulation of PI3K‐AKT‐β‐catenin pathways

MARCH1 encourages tumour progression of hepatocellular carcinoma via regulation of PI3K‐AKT‐β‐catenin pathways

Pathogenic diversity of RNA variants and RNA variation-associated factors in cancer development

Recent Advances in RNA Therapeutics and RNA Delivery Systems Based on Nanoparticles

Contact Info

Product

Resources

About